{"transactions":[{"id":750810,"issuer":{"id":608,"kind":"organization","name":"Outlook Therapeutics, Inc.","symbol":"OTLK"},"owners":[{"id":41619,"kind":"person","name":"Haddadin Yezan Munther","position":1,"cik":"0001718004","reported_name":"Haddadin Yezan Munther","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-03T22:03:16.000Z","date":"2026-06-02","kind":"purchase","planned":false,"acquired":true,"shares":29000,"price":0.8326,"value":24145.4,"ownership":{"direct":true},"balance_after":66167,"source":{"system":"sec-edgar","filing":"0001649989-26-000005","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1649989/000164998926000005/primary_doc.xml","form_type":"4"}},{"id":761233,"issuer":{"id":608,"kind":"organization","name":"Outlook Therapeutics, Inc.","symbol":"OTLK"},"owners":[{"id":41619,"kind":"person","name":"Haddadin Yezan Munther","position":1,"cik":"0001718004","reported_name":"Haddadin Yezan Munther","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-27T19:24:20.000Z","date":"2026-05-26","kind":"purchase","planned":false,"acquired":true,"shares":34000,"price":0.44,"value":14960.0,"ownership":{"direct":true},"balance_after":37167,"source":{"system":"sec-edgar","filing":"0001649989-26-000003","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1649989/000164998926000003/primary_doc.xml","form_type":"4"}},{"id":1024020,"issuer":{"id":608,"kind":"organization","name":"Outlook Therapeutics, Inc.","symbol":"OTLK"},"owners":[{"id":41619,"kind":"person","name":"Haddadin Yezan Munther","position":1,"cik":"0001718004","reported_name":"Haddadin Yezan Munther","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-10-03T23:20:43.000Z","date":"2025-10-03","kind":"grant","planned":false,"acquired":true,"shares":95969,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options were granted under the 2024 Plan in lieu of $90,000 cash fees payable under the Issuer's Non-Employee Director Compensation Policy and vest in four equal quarterly installments on the last day of each fiscal quarter such that they are vested in full on September 30, 2026, subject to the Reporting Person providing continuous service to the Issuer on such date and subject to acceleration upon a Change in Control as defined in the 2024 Plan, subject to the Reporting Person providing continuous service to the Issuer immediately prior to such Change in Control."}],"balance_after":95969,"derivative":{"exercise_price":1.06,"expiration_date":"2035-10-03","underlying":"Common Stock","underlying_shares":95969},"source":{"system":"sec-edgar","filing":"0001649989-25-000006","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1649989/000164998925000006/primary_doc.xml","form_type":"4"}},{"id":1024019,"issuer":{"id":608,"kind":"organization","name":"Outlook Therapeutics, Inc.","symbol":"OTLK"},"owners":[{"id":41619,"kind":"person","name":"Haddadin Yezan Munther","position":1,"cik":"0001718004","reported_name":"Haddadin Yezan Munther","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-10-03T23:20:43.000Z","date":"2025-10-01","kind":"grant","planned":false,"acquired":true,"shares":286734,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option grant is an annual stock option grant under the Issuer's Non-Employee Director Compensation Policy and the Issuer's 2024 Equity Incentive Plan (the \"2024 Plan\") and shall fully vest on October 1, 2026, subject to the Reporting Person providing continuous service to the Issuer on such date. In addition, the shares underlying the options are subject to acceleration upon a Change in Control as defined in the 2024 Plan, subject to the Reporting Person providing continuous service to the Issuer immediately prior to such Change in Control."}],"balance_after":286734,"derivative":{"exercise_price":1.04,"expiration_date":"2035-10-01","underlying":"Common Stock","underlying_shares":286734},"source":{"system":"sec-edgar","filing":"0001649989-25-000006","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1649989/000164998925000006/primary_doc.xml","form_type":"4"}},{"id":1391403,"issuer":{"id":608,"kind":"organization","name":"Outlook Therapeutics, Inc.","symbol":"OTLK"},"owners":[{"id":41619,"kind":"person","name":"Haddadin Yezan Munther","position":1,"cik":"0001718004","reported_name":"Haddadin Yezan Munther","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-10-04T00:30:10.000Z","date":"2024-10-03","kind":"grant","planned":false,"acquired":true,"shares":19771,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The options were granted under the 2024 Plan in lieu of $90,000 cash fees payable under the Issuer's Non-Employee Director Compensation Policy and vest in four equal quarterly installments on the last day of each fiscal quarter such that they are vested in full on September 30, 2025, subject to the Reporting Person providing continuous service to the Issuer on such date and subject to acceleration upon a Change in Control as defined in the 2024 Plan, subject to the Reporting Person providing continuous service to the Issuer immediately prior to such Change in Control."}],"balance_after":19771,"derivative":{"exercise_price":5.25,"expiration_date":"2034-10-03","underlying":"Common Stock","underlying_shares":19771},"source":{"system":"sec-edgar","filing":"0001415889-24-024704","document":"form4-10032024_081007.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1649989/000141588924024704/form4-10032024_081007.xml","form_type":"4"}},{"id":1391402,"issuer":{"id":608,"kind":"organization","name":"Outlook Therapeutics, Inc.","symbol":"OTLK"},"owners":[{"id":41619,"kind":"person","name":"Haddadin Yezan Munther","position":1,"cik":"0001718004","reported_name":"Haddadin Yezan Munther","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-10-04T00:30:10.000Z","date":"2024-10-01","kind":"grant","planned":false,"acquired":true,"shares":132293,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option grant was made under the 2024 Plan and shall fully vest on October 1, 2025, subject to the Reporting Person providing continuous service to the Issuer on such date. In addition, the shares underlying the options are subject to acceleration upon a Change in Control as defined in the 2024 Plan, subject to the Reporting Person providing continuous service to the Issuer immediately prior to such Change in Control."}],"balance_after":132293,"derivative":{"exercise_price":5.22,"expiration_date":"2034-10-01","underlying":"Common Stock","underlying_shares":132293},"source":{"system":"sec-edgar","filing":"0001415889-24-024704","document":"form4-10032024_081007.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1649989/000141588924024704/form4-10032024_081007.xml","form_type":"4"}},{"id":1391401,"issuer":{"id":608,"kind":"organization","name":"Outlook Therapeutics, Inc.","symbol":"OTLK"},"owners":[{"id":41619,"kind":"person","name":"Haddadin Yezan Munther","position":1,"cik":"0001718004","reported_name":"Haddadin Yezan Munther","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-10-04T00:30:10.000Z","date":"2024-10-01","kind":"grant","planned":false,"acquired":true,"shares":56636,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option grant is an annual stock option grant under the Issuer's Non-Employee Director Compensation Policy and the Issuer's 2024 Equity Incentive Plan (the \"2024 Plan\") and shall fully vest on October 1, 2025, subject to the Reporting Person providing continuous service to the Issuer on such date. In addition, the shares underlying the options are subject to acceleration upon a Change in Control as defined in the 2024 Plan, subject to the Reporting Person providing continuous service to the Issuer immediately prior to such Change in Control."}],"balance_after":56636,"derivative":{"exercise_price":5.22,"expiration_date":"2034-10-01","underlying":"Common Stock","underlying_shares":56636},"source":{"system":"sec-edgar","filing":"0001415889-24-024704","document":"form4-10032024_081007.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1649989/000141588924024704/form4-10032024_081007.xml","form_type":"4"}},{"id":1557416,"issuer":{"id":608,"kind":"organization","name":"Outlook Therapeutics, Inc.","symbol":"OTLK"},"owners":[{"id":41619,"kind":"person","name":"Haddadin Yezan Munther","position":1,"cik":"0001718004","reported_name":"Haddadin Yezan Munther","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-03-29T14:39:09.000Z","date":"2024-03-28","kind":"purchase","planned":false,"acquired":true,"shares":1881.7112,"price":11.82,"value":22241.826384,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $11.78 to $11.8249 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Reflects the Issuer's 1-for-20 reverse stock split effected on March 13, 2024."}],"balance_after":5048.7112,"source":{"system":"sec-edgar","filing":"0001415889-24-009394","document":"form4-03292024_020304.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1649989/000141588924009394/form4-03292024_020304.xml","form_type":"4"}},{"id":1585936,"issuer":{"id":608,"kind":"organization","name":"Outlook Therapeutics, Inc.","symbol":"OTLK"},"owners":[{"id":41619,"kind":"person","name":"Haddadin Yezan Munther","position":1,"cik":"0001718004","reported_name":"Haddadin Yezan Munther","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-03-08T21:11:11.000Z","date":"2024-03-07","kind":"grant","planned":false,"acquired":true,"shares":94441,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options were granted under the Issuer's 2015 Equity Incentive Plan (the \"2015 Plan\") and shall fully vest on the earlier of (i) March 7, 2025; or (ii) the date of the Issuer's next annual meeting of stockholders, in each case subject to the Reporting Person providing continuous service to the Issuer on such date. In addition, the shares underlying the options are subject to acceleration upon a Change in Control as defined in the 2015 Plan, subject to the Reporting Person providing continuous service to the Issuer immediately prior to such Change in Control."}],"balance_after":94441,"derivative":{"exercise_price":0.41,"expiration_date":"2034-03-07","underlying":"Common Stock","underlying_shares":94441},"source":{"system":"sec-edgar","filing":"0001415889-24-007332","document":"form4-03082024_090358.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1649989/000141588924007332/form4-03082024_090358.xml","form_type":"4"}},{"id":1764192,"issuer":{"id":608,"kind":"organization","name":"Outlook Therapeutics, Inc.","symbol":"OTLK"},"owners":[{"id":41619,"kind":"person","name":"Haddadin Yezan Munther","position":1,"cik":"0001718004","reported_name":"Haddadin Yezan Munther","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-10-05T21:07:18.000Z","date":"2023-10-04","kind":"grant","planned":false,"acquired":true,"shares":358337,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options were granted under the 2015 Plan in lieu of $75,000 cash fees payable under the Issuer's non-employee Director compensation program and vest in four equal quarterly installments on the last day of each fiscal quarter such that they are vested in full on September 30, 2024, subject to the Reporting Person providing continuous service to the Issuer on such date and subject to acceleration upon a Change in Control as defined in the 2015 Plan."}],"balance_after":358337,"derivative":{"exercise_price":0.24,"expiration_date":"2033-10-04","underlying":"Common Stock","underlying_shares":358337},"source":{"system":"sec-edgar","filing":"0001209191-23-052235","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1649989/000120919123052235/doc4.xml","form_type":"4"}},{"id":1933736,"issuer":{"id":608,"kind":"organization","name":"Outlook Therapeutics, Inc.","symbol":"OTLK"},"owners":[{"id":41619,"kind":"person","name":"Haddadin Yezan Munther","position":1,"cik":"0001718004","reported_name":"Haddadin Yezan Munther","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-03-31T21:50:58.000Z","date":"2023-03-29","kind":"grant","planned":false,"acquired":true,"shares":41065,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options were granted under the Issuer's 2015 Equity Incentive Plan (the \"2015 Plan\") and shall fully vest on the earlier of (i) March 29,2024; or (ii) the date of the Issuer's next annual meeting of stockholders, in each case subject to the Reporting Person providing continuous service to the Issuer on such date. In addition, the shares underlying the options are subject to acceleration upon a Change in Control as defined in the 2015 Plan, subject to the Reporting Person providing continuous service to the Issuer immediately prior to such Change in Control."}],"balance_after":41065,"derivative":{"exercise_price":1.05,"expiration_date":"2033-03-29","underlying":"Common Stock","underlying_shares":41065},"source":{"system":"sec-edgar","filing":"0001209191-23-021913","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1649989/000120919123021913/doc4.xml","form_type":"4"}},{"id":2138918,"issuer":{"id":608,"kind":"organization","name":"Outlook Therapeutics, Inc.","symbol":"OTLK"},"owners":[{"id":41619,"kind":"person","name":"Haddadin Yezan Munther","position":1,"cik":"0001718004","reported_name":"Haddadin Yezan Munther","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-10-11T21:05:51.000Z","date":"2022-10-07","kind":"purchase","acquired":true,"shares":3600,"price":1.27,"value":4572.0,"ownership":{"direct":true},"balance_after":63343,"source":{"system":"sec-edgar","filing":"0001209191-22-053354","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1649989/000120919122053354/doc4.xml","form_type":"4"}},{"id":2138917,"issuer":{"id":608,"kind":"organization","name":"Outlook Therapeutics, Inc.","symbol":"OTLK"},"owners":[{"id":41619,"kind":"person","name":"Haddadin Yezan Munther","position":1,"cik":"0001718004","reported_name":"Haddadin Yezan Munther","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-10-11T21:05:51.000Z","date":"2022-10-06","kind":"purchase","acquired":true,"shares":29743,"price":1.29,"value":38368.47,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.279 - $1.2915, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4."}],"balance_after":59743,"source":{"system":"sec-edgar","filing":"0001209191-22-053354","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1649989/000120919122053354/doc4.xml","form_type":"4"}},{"id":2140059,"issuer":{"id":608,"kind":"organization","name":"Outlook Therapeutics, Inc.","symbol":"OTLK"},"owners":[{"id":41619,"kind":"person","name":"Haddadin Yezan Munther","position":1,"cik":"0001718004","reported_name":"Haddadin Yezan Munther","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-10-07T20:39:36.000Z","date":"2022-10-05","kind":"grant","acquired":true,"shares":71998,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options were granted under the 2015 Plan in lieu of $75,000 cash fees payable under the Issuer's non-employee Director compensation program and vest in four equal quarterly installments on the last day of each fiscal quarter such that they are vested in full on September 30, 2023, subject to the Reporting Person providing continuous service to the Issuer on such date and subject to acceleration upon a Change in Control as defined in the 2015 Plan."}],"balance_after":71998,"derivative":{"exercise_price":1.25,"expiration_date":"2032-10-05","underlying":"Common Stock","underlying_shares":71998},"source":{"system":"sec-edgar","filing":"0001209191-22-053123","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1649989/000120919122053123/doc4.xml","form_type":"4"}},{"id":2318567,"issuer":{"id":608,"kind":"organization","name":"Outlook Therapeutics, Inc.","symbol":"OTLK"},"owners":[{"id":41619,"kind":"person","name":"Haddadin Yezan Munther","position":1,"cik":"0001718004","reported_name":"Haddadin Yezan Munther","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-03-24T21:39:38.000Z","date":"2022-03-23","kind":"grant","acquired":true,"shares":21878,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options were granted under the Issuer's 2015 Equity Incentive Plan (the \"2015 Plan\") and shall fully vest on the earlier of (i) March 23,2023; or (ii) the date of the Issuer's next annual meeting of stockholders, in each case subject to the Reporting Person providing continuous service to the Issuer on such date. In addition, the shares underlying the options are subject to acceleration upon a Change in Control as defined in the 2015 Plan, subject to the Reporting Person providing continuous service to the Issuer immediately prior to such Change in Control."}],"balance_after":21878,"derivative":{"exercise_price":1.92,"expiration_date":"2032-03-23","underlying":"Common Stock","underlying_shares":21878},"source":{"system":"sec-edgar","filing":"0001209191-22-020952","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1649989/000120919122020952/doc4.xml","form_type":"4"}},{"id":2488069,"issuer":{"id":608,"kind":"organization","name":"Outlook Therapeutics, Inc.","symbol":"OTLK"},"owners":[{"id":41619,"kind":"person","name":"Haddadin Yezan Munther","position":1,"cik":"0001718004","reported_name":"Haddadin Yezan Munther","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-12-02T22:09:20.000Z","date":"2021-12-02","kind":"purchase","acquired":true,"shares":10000,"price":1.39,"value":13900.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.385 - $1.39, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4."}],"balance_after":30000,"source":{"system":"sec-edgar","filing":"0001209191-21-067650","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1649989/000120919121067650/doc4.xml","form_type":"4"}},{"id":2546063,"issuer":{"id":608,"kind":"organization","name":"Outlook Therapeutics, Inc.","symbol":"OTLK"},"owners":[{"id":41619,"kind":"person","name":"Haddadin Yezan Munther","position":1,"cik":"0001718004","reported_name":"Haddadin Yezan Munther","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-10-07T21:06:05.000Z","date":"2021-10-05","kind":"grant","acquired":true,"shares":47335,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options were granted under the 2015 Plan in lieu of $82,500 cash fees payable under the Issuers's non-employee Director compensation program and vest in four equal quarterly installments on the last day of each fiscal quarter such that they are vested in full on September 30, 2022, subject to the Reporting Person providing continuous service to the Issuer on such date and subject to acceleration upon a Change in Control as defined in the 2015 Plan."}],"balance_after":47335,"derivative":{"exercise_price":2.12,"expiration_date":"2031-10-05","underlying":"Common Stock","underlying_shares":47335},"source":{"system":"sec-edgar","filing":"0001209191-21-059950","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1649989/000120919121059950/doc4.xml","form_type":"4"}},{"id":2743809,"issuer":{"id":608,"kind":"organization","name":"Outlook Therapeutics, Inc.","symbol":"OTLK"},"owners":[{"id":41619,"kind":"person","name":"Haddadin Yezan Munther","position":1,"cik":"0001718004","reported_name":"Haddadin Yezan Munther","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-04-20T23:56:22.000Z","date":"2021-04-19","kind":"purchase","acquired":true,"shares":10000,"price":1.82,"value":18200.0,"ownership":{"direct":true},"balance_after":20000,"source":{"system":"sec-edgar","filing":"0001209191-21-027685","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1649989/000120919121027685/doc4.xml","form_type":"4"}},{"id":2770244,"issuer":{"id":608,"kind":"organization","name":"Outlook Therapeutics, Inc.","symbol":"OTLK"},"owners":[{"id":41619,"kind":"person","name":"Haddadin Yezan Munther","position":1,"cik":"0001718004","reported_name":"Haddadin Yezan Munther","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-03-26T22:08:09.000Z","date":"2021-03-24","kind":"grant","acquired":true,"shares":20873,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options were granted under the Issuer's 2015 Equity Incentive Plan (the \"2015 Plan\") and shall vest in full on March 24, 2022, subject to the Reporting Person providing continuous service to the Issuer on such date and subject to acceleration upon a Change in Control as defined in the 2015 Plan, subject to the Reporting Person providing continuous service to the Issuer through such event."}],"balance_after":20873,"derivative":{"exercise_price":2.27,"expiration_date":"2031-03-24","underlying":"Common Stock","underlying_shares":20873},"source":{"system":"sec-edgar","filing":"0001209191-21-023283","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1649989/000120919121023283/doc4.xml","form_type":"4"}},{"id":3012409,"issuer":{"id":608,"kind":"organization","name":"Outlook Therapeutics, Inc.","symbol":"OTLK"},"owners":[{"id":41619,"kind":"person","name":"Haddadin Yezan Munther","position":1,"cik":"0001718004","reported_name":"Haddadin Yezan Munther","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-10-05T22:47:09.000Z","date":"2020-10-05","kind":"grant","acquired":true,"shares":160474,"price":0.5141,"value":82499.6834,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options were granted under the 2015 Plan in lieu of $82,500 cash fees payable under the Issuers's non-employee Director compensation program and vest in four equal quarterly installments on the last day of each fiscal quarter such that they are vested in full on September 30, 2021, subject to the Reporting Person providing continuous service to the Issuer on such date and subject to acceleration upon a Change in Control as defined in the 2015 Plan."}],"balance_after":160474,"derivative":{"exercise_price":0.7052,"expiration_date":"2030-10-05","underlying":"Common Stock","underlying_shares":160474},"source":{"system":"sec-edgar","filing":"0001209191-20-053873","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1649989/000120919120053873/doc4.xml","form_type":"4"}},{"id":3012408,"issuer":{"id":608,"kind":"organization","name":"Outlook Therapeutics, Inc.","symbol":"OTLK"},"owners":[{"id":41619,"kind":"person","name":"Haddadin Yezan Munther","position":1,"cik":"0001718004","reported_name":"Haddadin Yezan Munther","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-10-05T22:47:09.000Z","date":"2020-10-01","kind":"grant","acquired":true,"shares":290372,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options were granted under the Issuer's 2015 Equity Incentive Plan (the \"2015 Plan\") and shall vest in full on October 1, 2021, subject to the Reporting Person providing continuous service to the Issuer on such date and subject to acceleration upon a Change in Control as defined in the 2015 Plan, subject to the Reporting Person providing continuous service to the Issuer through such event."}],"balance_after":290372,"derivative":{"exercise_price":0.71,"expiration_date":"2030-10-01","underlying":"Common Stock","underlying_shares":290372},"source":{"system":"sec-edgar","filing":"0001209191-20-053873","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1649989/000120919120053873/doc4.xml","form_type":"4"}},{"id":3024397,"issuer":{"id":608,"kind":"organization","name":"Outlook Therapeutics, Inc.","symbol":"OTLK"},"owners":[{"id":41619,"kind":"person","name":"Haddadin Yezan Munther","position":1,"cik":"0001718004","reported_name":"Haddadin Yezan Munther","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-09-22T21:14:01.000Z","date":"2020-09-22","kind":"purchase","acquired":true,"shares":10000,"price":0.7245,"value":7245.0,"ownership":{"direct":true},"balance_after":10000,"source":{"system":"sec-edgar","filing":"0001209191-20-051507","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1649989/000120919120051507/doc4.xml","form_type":"4"}},{"id":3078526,"issuer":{"id":608,"kind":"organization","name":"Outlook Therapeutics, Inc.","symbol":"OTLK"},"owners":[{"id":41619,"kind":"person","name":"Haddadin Yezan Munther","position":1,"cik":"0001718004","reported_name":"Haddadin Yezan Munther","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-07-21T22:06:48.000Z","date":"2020-07-17","kind":"grant","acquired":true,"shares":135000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options were granted under the Issuer's 2015 Equity Incentive Plan (the \"2015 Plan\") and shall vest in full on July 17, 2021, subject to the Reporting Person providing continuous service to the Issuer on such date and subject to acceleration upon a Change in Control as defined in the 2015 Plan, subject to the Reporting Person providing continuous service to the Issuer through such event."}],"balance_after":135000,"derivative":{"exercise_price":1.58,"expiration_date":"2030-07-17","underlying":"Common Stock","underlying_shares":135000},"source":{"system":"sec-edgar","filing":"0001209191-20-043218","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1649989/000120919120043218/doc4.xml","form_type":"4"}},{"id":3198904,"issuer":{"id":608,"kind":"organization","name":"Outlook Therapeutics, Inc.","symbol":"OTLK"},"owners":[{"id":41619,"kind":"person","name":"Haddadin Yezan Munther","position":1,"cik":"0001718004","reported_name":"Haddadin Yezan Munther","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-03-20T21:52:52.000Z","date":"2020-03-19","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options were granted under the Issuer's 2015 Equity Incentive Plan (the \"2015 Plan\") and shall vest in full on March 19, 2021, subject to the Reporting Person providing continuous service to the Issuer on such date and subject to acceleration upon a Change in Control as defined in the 2015 Plan, subject to the Reporting Person providing continuous service to the Issuer through such event."}],"balance_after":15000,"derivative":{"exercise_price":0.54,"expiration_date":"2030-03-19","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001209191-20-020509","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1649989/000120919120020509/doc4.xml","form_type":"4"}},{"id":3317389,"issuer":{"id":608,"kind":"organization","name":"Outlook Therapeutics, Inc.","symbol":"OTLK"},"owners":[{"id":41619,"kind":"person","name":"Haddadin Yezan Munther","position":1,"cik":"0001718004","reported_name":"Haddadin Yezan Munther","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-01-07T01:29:21.000Z","date":"2020-01-02","kind":"grant","acquired":true,"shares":5980,"price":0.9853,"value":5892.094,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options were granted under the 2015 Plan in lieu of $5,892.86 cash fees payable under the Issuers's non-employee Director compensation program and vest in three equal quarterly installments on the last day of each remaining fiscal quarter (3/31, 6/30 and 9/30) such that they are vested in full on September 30, 2020, subject to the Reporting Person providing continuous service to the Issuer on such date and subject to acceleration upon a Change in Control as defined in the 2015 Plan."}],"balance_after":5980,"derivative":{"exercise_price":0.875,"expiration_date":"2030-01-02","underlying":"Common Stock","underlying_shares":5980},"source":{"system":"sec-edgar","filing":"0001209191-20-002167","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1649989/000120919120002167/doc4.xml","form_type":"4"}},{"id":3396441,"issuer":{"id":608,"kind":"organization","name":"Outlook Therapeutics, Inc.","symbol":"OTLK"},"owners":[{"id":41619,"kind":"person","name":"Haddadin Yezan Munther","position":1,"cik":"0001718004","reported_name":"Haddadin Yezan Munther","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-10-07T22:11:45.000Z","date":"2019-10-03","kind":"grant","acquired":true,"shares":80176,"price":0.9853,"value":78997.4128,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options were granted under the 2015 Plan in lieu of $79,000 cash fees payable under the Issuers's non-employee Director compensation program and vest in four equal quarterly installments on the last day of each fiscal quarter such that they are vested in full on September 30, 2020, subject to the Reporting Person providing continuous service to the Issuer on such date and subject to acceleration upon a Change in Control as defined in the 2015 Plan."}],"balance_after":80176,"derivative":{"exercise_price":1.4,"expiration_date":"2029-10-03","underlying":"Common Stock","underlying_shares":80176},"source":{"system":"sec-edgar","filing":"0001209191-19-052712","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1649989/000120919119052712/doc4.xml","form_type":"4"}},{"id":3396440,"issuer":{"id":608,"kind":"organization","name":"Outlook Therapeutics, Inc.","symbol":"OTLK"},"owners":[{"id":41619,"kind":"person","name":"Haddadin Yezan Munther","position":1,"cik":"0001718004","reported_name":"Haddadin Yezan Munther","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-10-07T22:11:45.000Z","date":"2019-10-03","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options were granted under the Issuer's 2015 Equity Incentive Plan (the \"2015 Plan\") and shall vest in full on the one year anniversary of the grant date, subject to the Reporting Person providing continuous service to the Issuer on such date and subject to acceleration upon a Change in Control as defined in the 2015 Plan."}],"balance_after":15000,"derivative":{"exercise_price":1.4,"expiration_date":"2029-10-03","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001209191-19-052712","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1649989/000120919119052712/doc4.xml","form_type":"4"}},{"id":4174297,"issuer":{"id":608,"kind":"organization","name":"Outlook Therapeutics, Inc.","symbol":"OTLK"},"owners":[{"id":41619,"kind":"person","name":"Haddadin Yezan Munther","position":1,"cik":"0001718004","reported_name":"Haddadin Yezan Munther","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2017-11-02T22:13:09.000Z","date":"2017-10-31","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"33.33% of the shares underlying the option shall vest on each of the first, second and third anniversaries of the grant date, such that 100% of the shares underlying the option shall be vested on October 31, 2020, subject to the Reporting Person providing continued service through such date."}],"balance_after":25000,"derivative":{"exercise_price":1.26,"expiration_date":"2027-10-31","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001209191-17-058966","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1649989/000120919117058966/doc4.xml","form_type":"4"}}]}